#1 Clinical Trials Search in Europe

Meglumine Gadoterate

Meglumine Gadoterate, also known as gadoteric acid, is a contrast agent used in magnetic resonance imaging (MRI) scans. This article explores recent clinical trials investigating the use of Meglumine Gadoterate in patients with relapsing multiple sclerosis and severe hyponatremia. These studies aim to evaluate the drug’s effectiveness in enhancing brain lesion visibility and its potential role in preventing sodium overcorrection in certain medical conditions.

Table of Contents

What is Meglumine Gadoterate?

Meglumine Gadoterate, also known as Gadoteric acid or Gadoterate meglumine, is a medical contrast agent used in radiology[1]. It belongs to a class of drugs called gadolinium-based contrast agents (GBCAs). These substances are used to enhance the quality of magnetic resonance imaging (MRI) scans, making certain tissues or abnormalities more visible to doctors.

Medical Uses

Meglumine Gadoterate is primarily used in magnetic resonance imaging (MRI) procedures. It helps to improve the visibility of internal body structures during MRI scans, which can be crucial for diagnosing various conditions. Some of the medical uses include:

  • Detecting and monitoring brain lesions in patients with multiple sclerosis (MS)[1]
  • Enhancing the visibility of tumors or other abnormalities in the brain and spine
  • Assisting in the diagnosis of various neurological conditions
  • Helping to visualize blood vessels and assess blood flow in different parts of the body

How it Works

Meglumine Gadoterate contains gadolinium, a rare earth metal. When injected into the body, it circulates in the bloodstream and accumulates in certain tissues. The gadolinium atoms affect the magnetic properties of nearby water molecules, which results in a brighter or enhanced signal on MRI images. This enhancement allows radiologists to better distinguish between normal and abnormal tissues, making diagnoses more accurate[1].

Administration

Meglumine Gadoterate is typically administered through intravenous injection (into a vein) just before or during an MRI scan[2]. The dosage is usually calculated based on the patient’s body weight, with a typical dose being around 0.2 milliliters per kilogram of body weight. It’s important to note that this medication should only be administered by healthcare professionals in a clinical setting.

Safety and Precautions

While Meglumine Gadoterate is generally considered safe, there are some precautions to be aware of:

  • Allergic reactions: Although rare, some people may be allergic to gadolinium-based contrast agents. Inform your doctor of any allergies before the procedure.
  • Kidney function: Patients with severely impaired kidney function may be at risk of a rare condition called nephrogenic systemic fibrosis (NSF). Your doctor will assess your kidney function before administering the contrast agent.
  • Pregnancy and breastfeeding: If you are pregnant or breastfeeding, inform your doctor as special considerations may apply.

Ongoing Research

Meglumine Gadoterate is currently being used in clinical trials to further understand its applications and effectiveness. For example, it’s being used in a study investigating new treatments for relapsing multiple sclerosis (RMS)[1]. In this study, Meglumine Gadoterate is used to enhance MRI scans, allowing researchers to count the number of new brain lesions in patients with RMS. This helps to evaluate the effectiveness of a new drug being tested for MS treatment.

Another study is using Meglumine Gadoterate in MRI scans to assess potential brain damage in patients who have experienced severe hyponatremia (low sodium levels in the blood)[2]. This demonstrates how this contrast agent can be valuable in various areas of medical research and diagnosis beyond its primary use in MS.

Aspect Details
Drug Name Meglumine Gadoterate (Gadoteric Acid)
Primary Use Contrast agent for MRI scans
Administration Intravenous injection
Dosage Up to 0.2 ml/kg body weight
Clinical Trial Applications 1. Relapsing Multiple Sclerosis
2. Severe Hyponatremia
Main Objectives 1. Evaluate new T1 GdE lesions in MS patients
2. Assess brain changes in hyponatremia patients
Key Eligibility Criteria 1. RMS with recent disease activity
2. Severe hyponatremia requiring ICU admission
Safety Considerations Already approved for MRI use; specific trial risks not detailed

FAQ

  • What is Meglumine Gadoterate used for in clinical trials? Meglumine Gadoterate is primarily used as a contrast agent in MRI scans. In the clinical trials discussed, it is used to enhance the visibility of brain lesions in patients with relapsing multiple sclerosis and to assist in brain imaging for patients with severe hyponatremia.
  • How is Meglumine Gadoterate administered in these trials? In the trials, Meglumine Gadoterate is administered intravenously (through a vein). The dosage is typically measured in milliliters per kilogram of body weight, with a maximum daily dose of 0.2 ml/kg.
  • What are the main objectives of the clinical trials using Meglumine Gadoterate? The main objectives include evaluating the efficacy of new treatments for relapsing multiple sclerosis by measuring new T1 Gadolinium-Enhancing (GdE) lesions on MRI scans, and assessing brain changes in patients with severe hyponatremia to prevent complications from rapid sodium correction.
  • Are there any specific eligibility criteria for participants in these trials? Yes, eligibility criteria vary depending on the trial. For the multiple sclerosis trial, participants must have relapsing forms of MS, recent disease activity, and an Expanded Disability Status Scale (EDSS) score of 5.5 or less. For the hyponatremia trial, participants must have severe hyponatremia (low sodium levels) and be admitted to the ICU.
  • What are some potential risks or side effects associated with Meglumine Gadoterate? The trials don't specifically mention side effects of Meglumine Gadoterate. However, as with any contrast agent, there may be risks such as allergic reactions. It's important to note that the drug is already approved for use in MRI scans, and these trials are focusing on its application in specific medical conditions rather than testing the drug itself for safety.

Ongoing Clinical Trials on Meglumine Gadoterate

  • Study on Using Desmopressin Acetate Trihydrate to Prevent Sodium Overcorrection in Patients with Severe Hyponatremia

    Recruiting

    3 1 1 1
    Investigated drugs:
    France

  • A Study Comparing Gadopiclenol and Gadoterate Meglumine for Heart MRI Scans in Children with Congenital Heart Disease

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Long-term safety study of NNC6019-0001 for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Czechia France Germany Italy The Netherlands Portugal +1

  • Study on Hyperpolarized [1-13C]Pyruvate and Meglumine Gadoterate for Patients with Diabetic Kidney Disease

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Denmark

  • Study of LY3541860 and Meglumine Gadoterate for Adults with Relapsing Multiple Sclerosis

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Latvia Lithuania Poland +1

Glossary

  • Meglumine Gadoterate: A contrast agent used in magnetic resonance imaging (MRI) scans to enhance the visibility of certain tissues or abnormalities in the body.
  • Relapsing Multiple Sclerosis (RMS): A form of multiple sclerosis characterized by periods of new or worsening symptoms (relapses) followed by periods of recovery or remission.
  • T1 Gadolinium-Enhancing (GdE) Lesions: Areas of active inflammation or damage in the brain that become visible on MRI scans when a gadolinium-based contrast agent (like Meglumine Gadoterate) is used.
  • Hyponatremia: A condition where the sodium levels in the blood are abnormally low, which can lead to various neurological symptoms and complications.
  • Expanded Disability Status Scale (EDSS): A method of quantifying disability in multiple sclerosis, ranging from 0 to 10, with higher scores indicating greater disability.
  • Central Pontine Myelinolysis (CPM): A neurological disorder that can occur when sodium levels in the body are corrected too quickly, leading to damage in the brain stem.
  • Magnetic Resonance Imaging (MRI): A medical imaging technique that uses strong magnetic fields and radio waves to produce detailed images of the inside of the body.
  • Intravenous (IV): A method of administering medications or fluids directly into a vein.

References

  1. http://clinicaltrials.eu/trial/study-of-ly3541860-and-meglumine-gadoterate-for-adults-with-relapsing-multiple-sclerosis/
  2. http://clinicaltrials.eu/trial/study-on-using-desmopressin-acetate-trihydrate-to-prevent-sodium-overcorrection-in-patients-with-severe-hyponatremia/